Press Releases for MSFT

Press Releases
Ligand Completes Pharmacopeia Acquisition
Ligand Enters into Exclusive License Agreement with GlaxoSmithKline to License Rights to LGD-4665 and other Ligand Thrombopoietin (TPO) Molecules
Ligand Presents Positive LGD-4665 Clinical Trial Results at the American Society of Hematology Annual Meeting
GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Ligand Collaborator GlaxoSmithKline Receives FDA Approval for PROMACTA®
Ligand Pharmaceuticals Announces Third Quarter Results
Ligand and Pharmacopeia to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Ligand to Hold Third Quarter Results Conference Call on November 6
Ligand and Pharmacopeia to Present At the Oppenheimer 19th Annual Healthcare Conference
Ligand to Acquire Pharmacopeia for Stock and Contingent Value Rights
Ligand to Acquire Pharmacopeia for Stock and Contingent Value Rights
Beacon Equity Issues Technical Trade Alerts on Market Movers: GSAE, THMD, AKSN, LGND, CRAY, DAL
Ligand Pharmaceuticals and the SALK Institute Enter Settlement Agreement and Mutual Release of All Claims
Ligand Pharmaceuticals Appoints Dr. Stephen Sabba to Board of Directors
BeaconEquity.com Issues Trade Alerts on Market Movers: WEL, LGND, PPCO, KIDS, GNLK, VCSY
Ligand Pharmaceuticals Announces Second Quarter Results
Ligand to Hold Second Quarter Results Conference Call on July 31
Ligand Partner GlaxoSmithKline Receives FDA Extended Priority Review for PROMACTA(R) NDA
Ligand to Present at the Needham & Company Biotechnology and Medical Technology Conference on June 11
PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL
New Analyst Reports for SMURFIT STONE CONTAINER CORPORATION, INFOSYS TECHNOLOGIES LIMITED, COSTCO WHOLESALE CORP, and LIGAND PHARMACEUTICALS INCORPORATED
Mergent, Inc. Announces Changes to the HealthShares(TM) Composite Index, Dermatology and Wound Care Index and Orthopedic Repair Index - Correction
Mergent, Inc. Announces Changes to the HealthShares(TM) Composite Index, HealthShares(TM) Dermatology and Wound Care Index and HealthShares(TM) Orthopedic Repair Index
Ligand Pharmaceuticals Announces First Quarter Results
Ligand Initiates Phase II Trial with LGD-4665 in Idiopathic Thrombocytopenic Purpura
Ligand to Hold First Quarter Results Conference Call on May 1